Adult Dosing
Attention Deficit Hyperactivity Disorder
Adults and adolescents >70 kg
- Start PO 40mg/day
- Increase after a minimum of 3 days to PO 80mg/day or PO divided qd-bid; am and late afternoon/early evening
- After 2-4 wks, may increase to PO 100mg/day if needed
- Max: 100 mg/day
- If CYP2D6 inhibitors administered (eg, paroxetine, fluoxetine and quinidine), initiate at PO 40mg/day daily and increase to usual target dose of PO 80mg/day after 4 wks if symptoms fail to improve and initial dose is well tolerated
Adolescents up to 70 kg
- Start PO 0.5 mg/kg/day, increase after a minimum of 3 days to PO 1.2 mg/kg/day in a single dose or in two evenly divided doses, am and late afternoon/early evening
- Max: PO 1.4 mg/kg/day, or PO 100mg/day, whichever is less
- If CYP2D6 inhibitors administered (eg, paroxetine, fluoxetine and quinidine), initiate at 0.5 mg/kg/day and increase to usual target dose of 1.2 mg/kg/day after 4 wks if symptoms fail to improve and initial dose is well tolerated
Notes- Consume with or without food
- Discontinued without being tapered
- Not intended to be opened, they should be taken whole
- Safety and efficacy of single doses >120 mg and total daily doses >150 mg have not been established
Pediatric Dosing
Attention Deficit Hyperactivity Disorder
Children 
6 yrs and adolescents up to 70 kg
- Start PO 0.5 mg/kg/day, increase after a minimum of 3 days to PO 1.2 mg/kg/day in a single dose or in two evenly divided doses, am and late afternoon/early evening
- Max: PO 1.4 mg/kg/day, or PO 100mg/day, whichever is less
- If CYP2D6 inhibitors administered (eg, paroxetine, fluoxetine and quinidine), initiate at 0.5 mg/kg/day and increase to usual target dose of 1.2 mg/kg/day after 4 wks if symptoms fail to improve and initial dose is well tolerated
Notes- Safety and effectiveness in pediatric patients <6yr of age have not been established
- Consume with or without food
- Discontinued without being tapered
- Not intended to be opened, they should be taken whole
- Safety and efficacy of single doses >120 mg and total daily doses >150 mg have not been established
[Outline]
- Increased the risk of suicidal ideation have occurred in children and adolescents
- Monitor pediatric patients and observe closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the initial few months of a course of drug therapy, or at times of dose adjustments
- Closely monitor patients for emergence of suicidal symptoms, change therapeutic regimen or discontinue drug on presence of such symptoms
- Advice families and caregivers to monitor pediatric patients for emergence of agitation, irritability, unusual changes in behavior, emergence of suicidality, and to report such symptoms immediately to healthcare providers
- Discontinue drug in patients with jaundice or laboratory evidence of liver injury, avoid restarting of dose
- Structural cardiac abnormalities, other serious heart manifestations and fatal death have occurred, prohibit use in children or adolescents with known serious structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, or other serious cardiac problems
- Consider family history of sudden death or ventricular arrhythmia, perform electrocardiogram and echocardiogram, physical examination to assess for the presence of cardiac disease in patients on therapy
- Orthostatic hypotension and syncope have been reported in patients taking atomoxetine
- Use cautiously in any condition associated with abrupt heart rate or blood pressure changes, and condition that may predispose patients to hypotension
- Periodically measure pulse and blood pressure during therapy
- Increase in systolic and diastolic blood pressure, heart rate have occurred
- Treatment associated psychotic or manic symptoms have occurred
- Monitor patients for appearance or worsening of aggressive behavior or hostility
- Allergic reactions have occurred
- Rates of urinary retention and urinary hesitation may increase
- Reactions, including angioneurotic edema, rash, and urticaria, may occur
- Monitor growth during treatment
- May effect ability to drive and use heavy machines
Cautions: Use cautiously in
- Hepatic impairment
- History of cardiovascular disease
- Tachycardia
- Hypertension
- Hypotension
- Cerebrovascular disease
- Depression
- Pediatric
- Adolescent patients
- Suicide risk
- Poor CYP2D6 metabolizer
- Bipolar disorder
Pregnancy Category:C
Breastfeeding: Manufacturer advices caution.
Pricing data from www.DrugStore.com in U.S.A.
- Strattera 25 MG CAPS [Bottle] (LILLY)
30 mg = $190
90 mg = $536 - Strattera 80 MG CAPS [Bottle] (LILLY)
30 mg = $217.99
90 mg = $620.98 - Strattera 40 MG CAPS [Bottle] (LILLY)
30 mg = $202.98
90 mg = $569.95 - Strattera 10 MG CAPS [Bottle] (LILLY)
30 mg = $190
90 mg = $524.95 - Strattera 100 MG CAPS [Bottle] (LILLY)
30 mg = $217.99
90 mg = $620.98 - Strattera 60 MG CAPS [Bottle] (LILLY)
30 mg = $199.98
90 mg = $571.94 - Strattera 18 MG CAPS [Bottle] (LILLY)
30 mg = $190
90 mg = $554.94
Warning: This pricing information is subject to change at the sole discretion of DS Pharmacy. For the most current and up-to-date pricing information, please visit drugstore.com.
